128 related articles for article (PubMed ID: 10227448)
41. Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors.
Souid AK; Dubowy RL; Blaney SM; Hershon L; Sullivan J; McLeod WD; Bernstein ML
Clin Cancer Res; 2003 Feb; 9(2):703-10. PubMed ID: 12576438
[TBL] [Abstract][Full Text] [Related]
42. Amifostine protects against cisplatin-induced nephrotoxicity in a child with medulloblastoma.
Hayek M; Srinivasan A
Pediatr Hematol Oncol; 2003; 20(3):253-6. PubMed ID: 12637222
[No Abstract] [Full Text] [Related]
43. Protection against cisplatin-induced nephrotoxicity by recombinant human erythropoietin.
Yalcin S; Müftüoğlu S; Cetin E; Sarer B; Yildirim BA; Zeybek D; Orhan B
Med Oncol; 2003; 20(2):169-74. PubMed ID: 12835520
[TBL] [Abstract][Full Text] [Related]
44. The potential role of amifostine in conjunction with cisplatin in the treatment of locally advanced carcinoma of the cervix.
Wadler S; Goldberg G; Fields A; Anderson P; Beitler JJ; Sood B; Haynes H; Runowicz C
Semin Oncol; 1996 Aug; 23(4 Suppl 8):64-8. PubMed ID: 8783670
[TBL] [Abstract][Full Text] [Related]
45. The influence of active hexose correlated compound (AHCC) on cisplatin-evoked chemotherapeutic and side effects in tumor-bearing mice.
Hirose A; Sato E; Fujii H; Sun B; Nishioka H; Aruoma OI
Toxicol Appl Pharmacol; 2007 Jul; 222(2):152-8. PubMed ID: 17555784
[TBL] [Abstract][Full Text] [Related]
46. Neurologic protection by amifostine.
DiPaola RS; Schuchter L
Semin Oncol; 1999 Apr; 26(2 Suppl 7):82-8. PubMed ID: 10348265
[TBL] [Abstract][Full Text] [Related]
47. A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).
Gradishar WJ; Stephenson P; Glover DJ; Neuberg DS; Moore MR; Windschitl HE; Piel I; Abeloff MD
Cancer; 2001 Nov; 92(10):2517-22. PubMed ID: 11745184
[TBL] [Abstract][Full Text] [Related]
48. Chemopreventive doses of amifostine confer no cytoprotection to tumor nodules growing in the lungs of mice treated with cyclophosphamide.
Grdina DJ; Hunter N; Kataoka Y; Murley JS; Milas L
Semin Oncol; 1999 Apr; 26(2 Suppl 7):22-7. PubMed ID: 10348256
[TBL] [Abstract][Full Text] [Related]
49. Assessment of the protective effect of amifostine on radiation-induced pulmonary toxicity.
Vujaskovic Z; Feng QF; Rabbani ZN; Samulski TV; Anscher MS; Brizel DM
Exp Lung Res; 2002; 28(7):577-90. PubMed ID: 12396250
[TBL] [Abstract][Full Text] [Related]
50. Re: Sodium thiosulfate in cisplatin overdose by Erdlenbruch B et al., Med Pediatr Oncol 2002;38:349-352.
Bleyer A; Alberts DS
Med Pediatr Oncol; 2003 Jun; 40(6):413; author reply 414. PubMed ID: 12692822
[No Abstract] [Full Text] [Related]
51. Effects of amifostine and paclitaxel on growth of human ovarian carcinoma xenografts in the severe combined immune-deficient mouse: preliminary results.
Paine GD; Taylor CW; Lopez MH; Johnson CS; Capizzi RL
Semin Oncol; 1996 Aug; 23(4 Suppl 8):35-9. PubMed ID: 8783664
[TBL] [Abstract][Full Text] [Related]
52. HIF-1α siRNA and cisplatin in combination suppress tumor growth in a nude mice model of esophageal squamous cell carcinoma.
Liao HY; Wang GP; Gu LJ; Huang SH; Chen XL; Li Y; Cai SW
Asian Pac J Cancer Prev; 2012; 13(2):473-7. PubMed ID: 22524809
[TBL] [Abstract][Full Text] [Related]
53. Protection by amifostine of cyclophosphamide-induced myelosuppression.
Alberts DS
Semin Oncol; 1999 Apr; 26(2 Suppl 7):37-40. PubMed ID: 10348259
[TBL] [Abstract][Full Text] [Related]
54. Histoprotective effect of rutin against cisplatin-induced toxicities in tumor-bearing mice: Rutin lessens cisplatin-induced toxicities.
Prasad R; Prasad SB
Hum Exp Toxicol; 2021 Feb; 40(2):245-258. PubMed ID: 32787450
[TBL] [Abstract][Full Text] [Related]
55. [Side effects of postoperative radiochemotherapy with amifostine versus radiochemotherapy alone in head and neck tumors. Preliminary results of a prospective randomized trial].
Vacha P; Marx M; Engel A; Richter E; Feyerabend T
Strahlenther Onkol; 1999 Nov; 175 Suppl 4():18-22. PubMed ID: 10584135
[TBL] [Abstract][Full Text] [Related]
56. Prediction of treatment outcome by cisplatin-DNA adduct formation in patients with stage III/IV head and neck squamous cell carcinoma, treated by concurrent cisplatin-radiation (RADPLAT).
Hoebers FJ; Pluim D; Verheij M; Balm AJ; Bartelink H; Schellens JH; Begg AC
Int J Cancer; 2006 Aug; 119(4):750-6. PubMed ID: 16550603
[TBL] [Abstract][Full Text] [Related]
57. In vivo efficacy of marimastat and chemoradiation in head and neck cancer xenografts.
Skipper JB; McNally LR; Rosenthal EL; Wang W; Buchsbaum DJ
ORL J Otorhinolaryngol Relat Spec; 2009; 71(1):1-5. PubMed ID: 18931526
[TBL] [Abstract][Full Text] [Related]
58. The role of amifostine in the treatment of head and neck cancer with cisplatin-radiotherapy.
Marcu LG
Eur J Cancer Care (Engl); 2009 Mar; 18(2):116-23. PubMed ID: 19267726
[TBL] [Abstract][Full Text] [Related]
59. Tyrphostin 4-nitrobenzylidene malononitrile reduces chemotherapy toxicity without impairing efficacy.
Novogrodsky A; Weisspapir M; Patya M; Meshorer A; Vanichkin A
Cancer Res; 1998 Jun; 58(11):2397-403. PubMed ID: 9622080
[TBL] [Abstract][Full Text] [Related]
60. FK317, a novel substituted dihydrobenzoxazine, exhibits potent antitumor activity against human tumor xenografts in nude mice.
Naoe Y; Inami M; Matsumoto S; Takagaki S; Fujiwara T; Yamazaki S; Kawamura I; Nishigaki F; Tsujimoto S; Manda T; Shimomura K
Jpn J Cancer Res; 1998 Dec; 89(12):1306-17. PubMed ID: 10081492
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
